Association of Metabolic Dysfunction-associated Fatty Liver Disease with Gastrointestinal Infections: Insights from National Inpatient Sample Database

Overview

Journal BMJ Open Gastroenterol

Specialty Gastroenterology

Date 2024 Jan 18

PMID 38237944

Authors

Jay Patel

Aalam Sohal

Kanwal Bains

Hunza Chaudhry

Isha Kohli

Tejasvini Khanna

Dino Dukovic

Marina Roytman

Affiliations

Soon will be listed here.

Abstract

Objectives: The study aimed to compare the risk of gastrointestinal infections among patients with and without metabolic dysfunction-associated fatty liver disease (MAFLD).

Methods: This was a population-based, retrospective, observational study using data from the National Inpatient Sample (NIS), the largest all-payer US inpatient care database.

Setting: Hospitalisation of adults aged ≥18 years old admitted in 2020 was identified using the NIS. Patients were stratified by the presence and absence of MAFLD.

Participants: 26.4 million adults aged ≥18 years old were included in the study. Patients younger than 18 and those with missing demographic or mortality data were excluded.

Primary And Secondary Outcomes: Primary outcome was to assess the overall risk of gastrointestinal infections in patients with and without MAFLD. Secondary outcomes were demographics and comorbidities stratified by the presence or absence of gastrointestinal infection, and the risk of specific gastrointestinal pathogens.

Results: Of 26.4 million patients admitted in 2020, 755 910 (2.85%) had the presence of MAFLD. There was a higher prevalence of bacterial gastrointestinal infections in patients with MAFLD than those without (1.6% vs 0.9%, p<0.001). The incidence of (1.3% vs 0.8%, p<0.001), (0.3% vs 0.01%, p<0.001), and (0.07% vs 0.03%, p<0.001) was higher in patients with MAFLD. The presence of MAFLD was associated with higher odds of developing gastrointestinal infections (adjusted OR (aOR) -1.75, 95% CI -1.68 to 1.83, p<0.001). After adjusting for confounders, results remained statistically significant (aOR -1.36, 95% CI - 1.30-1.42, p<0.001).

Conclusion: Even after adjusting for confounding factors, our study demonstrates an increased risk of gastrointestinal infections in patients with MAFLD, specifically of , , and . The immune and microbiota changes seen within MAFLD potentially contribute to the increased risk of gastrointestinal infections.

Citing Articles

Nonalcoholic Fatty Liver Disease Increases the Risk of Lung Abscess: Findings from a Nationwide Cohort Study.

Lee E, Kim J, Yoon S J Clin Med. 2025; 14(2).

PMID: 39860549 PMC: 11765748. DOI: 10.3390/jcm14020542.

Association between MASLD and increased risk of serious bacterial infections requiring hospital admission: A meta-analysis.

Mantovani A, Morandin R, Fiorio V, Lando M, Gaviraghi A, Motta L Liver Int. 2024; 45(4):e16101.

PMID: 39258758 PMC: 11892334. DOI: 10.1111/liv.16101.

References

Zhang C, Shi L, Wang F . Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020; 5(5):428-430. PMC: 7129165. DOI: 10.1016/S2468-1253(20)30057-1. View

van Welzen B, Mudrikova T, El Idrissi A, Hoepelman A, Arends J . A Review of Non-Alcoholic Fatty Liver Disease in HIV-Infected Patients: The Next Big Thing?. Infect Dis Ther. 2019; 8(1):33-50. PMC: 6374241. DOI: 10.1007/s40121-018-0229-7. View

Wang B, Jiang X, Cao M, Ge J, Bao Q, Tang L . Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease. Sci Rep. 2016; 6:32002. PMC: 4994089. DOI: 10.1038/srep32002. View

Dulai P, Singh S, Patel J, Soni M, Prokop L, Younossi Z . Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology. 2017; 65(5):1557-1565. PMC: 5397356. DOI: 10.1002/hep.29085. View

Tsai M, Liu Y, Lin C, Wang C, Wu Y, Yong C . Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan. Nutrients. 2020; 12(3). PMC: 7146257. DOI: 10.3390/nu12030820. View

Ebrahimi F, Simon T, Hagstrom H, Soderling J, Wester A, Roelstraete B . Risk of Severe Infection in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease - A Population-based Cohort Study. Clin Gastroenterol Hepatol. 2023; 21(13):3346-3355.e19. DOI: 10.1016/j.cgh.2023.05.013. View

Samadan L, Jelicic M, Vince A, Papic N . Nonalcoholic Fatty Liver Disease-A Novel Risk Factor for Recurrent Infection. Antibiotics (Basel). 2021; 10(7). PMC: 8300633. DOI: 10.3390/antibiotics10070780. View

Abenavoli L, Scarpellini E, Colica C, Boccuto L, Salehi B, Sharifi-Rad J . Gut Microbiota and Obesity: A Role for Probiotics. Nutrients. 2019; 11(11). PMC: 6893459. DOI: 10.3390/nu11112690. View

Petersen C, Round J . Defining dysbiosis and its influence on host immunity and disease. Cell Microbiol. 2014; 16(7):1024-33. PMC: 4143175. DOI: 10.1111/cmi.12308. View

10.

Minhas A, Bhopalwala H, Dewaswala N, Salah H, Khan M, Shahid I . Association of Non-Alcoholic Fatty Liver Disease With in-Hospital Outcomes in Primary Heart Failure Hospitalizations With Reduced or Preserved Ejection Fraction. Curr Probl Cardiol. 2022; 48(8):101199. DOI: 10.1016/j.cpcardiol.2022.101199. View

11.

Adenote A, Dumic I, Madrid C, Barusya C, Nordstrom C, Rueda Prada L . NAFLD and Infection, a Nuanced Relationship. Can J Gastroenterol Hepatol. 2021; 2021:5556354. PMC: 8087474. DOI: 10.1155/2021/5556354. View

12.

Li P, He K, Li J, Liu Z, Gong J . The role of Kupffer cells in hepatic diseases. Mol Immunol. 2017; 85:222-229. DOI: 10.1016/j.molimm.2017.02.018. View

13.

Li F, Hao X, Chen Y, Bai L, Gao X, Lian Z . The microbiota maintain homeostasis of liver-resident γδT-17 cells in a lipid antigen/CD1d-dependent manner. Nat Commun. 2017; 7:13839. PMC: 5227332. DOI: 10.1038/ncomms13839. View

14.

Nseir W, Hussein S, Farah R, Mahamid M, Khatib H, Mograbi J . Nonalcoholic fatty liver disease as a risk factor for Clostridium difficile-associated diarrhea. QJM. 2019; 113(5):320-323. DOI: 10.1093/qjmed/hcz283. View

15.

Younossi Z, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M . Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015; 64(1):73-84. DOI: 10.1002/hep.28431. View

16.

Cheung O, Sanyal A . Hepatitis C infection and nonalcoholic fatty liver disease. Clin Liver Dis. 2008; 12(3):573-85, viii-ix. DOI: 10.1016/j.cld.2008.03.005. View

17.

Shah B, Hux J . Quantifying the risk of infectious diseases for people with diabetes. Diabetes Care. 2003; 26(2):510-3. DOI: 10.2337/diacare.26.2.510. View

18.

Bruns T, Zimmermann H, Stallmach A . Risk factors and outcome of bacterial infections in cirrhosis. World J Gastroenterol. 2014; 20(10):2542-54. PMC: 3949263. DOI: 10.3748/wjg.v20.i10.2542. View

19.

Hasa E, Hartmann P, Schnabl B . Liver cirrhosis and immune dysfunction. Int Immunol. 2022; 34(9):455-466. PMC: 9447994. DOI: 10.1093/intimm/dxac030. View

20.

Tang D, Kumar S . The Association Between Helicobacter pylori Infection and Nonalcoholic Fatty Liver Disease. Curr Gastroenterol Rep. 2017; 19(2):5. DOI: 10.1007/s11894-017-0545-1. View